Investor Presentaiton
Eurofins is experienced in successfully integrating
acquisitions and is returning to its historic M&A run rate
.
* eurofins
M&A has always been an integral part of Eurofins long-term strategy to build a unique bioanalytical testing platform for global leadership in its attractive high
growth and very scalable markets
From its IPO (Oct. 1997 to H1 2021 Eurofins has completed 411 acquisitions to consolidate the bioanalytical testing market, build leadership positions in its
markets, expand its portfolio of testing methods and customers, generate economies of scale and create barriers to entry. Since 1 July 2021, Eurofins has
completed 7 acquisitions including the acquisition of DNA Diagnostics Center ("DDC").
2017 and 2018 were two exceptional years of M&A activity as unique opportunities became available during that time, including EAG Laboratories, Covance Food
Solutions and TestAmerica
Since 2019, Eurofins reverted back to its normal M&A activity. In the coming years the Group will focus more on operational excellence than M&A since the most
strategic acquisitions have already been completed and the laboratory network in the U.S. for Food and Environment Testing is now largely completed
Average number of
acquisitions
60
50
40
30
127
347
56
235
per year
10
18
10
per year
per year
0
IPO-2010
2011-2016
2017-2018
373
26
26
2019
399
2020
450
411
400
350
300
250
200
150
100
12
50
0
H1 2021
Cumulative number of
acquisitions
Average number of acquisitions completed
Cumulative number of acquisitions completed
Eurofins has a long track record of acquiring and successfully integrating acquired businesses
24View entire presentation